Skip to content
StackItSmart
BHuman cohort / observational

Kisspeptin-10

KP-10

Kisspeptin-10 (KP-10) is the minimal biologically active 10-amino-acid C-terminal fragment of kisspeptin, the KISS1 gene product and endogenous agonist at the KISS1R/GPR54 receptor. It sits at the very top of the reproductive (hypothalamic-pituitary-gonadal, HPG) axis: it stimulates hypothalamic GnRH neurons, which drives pituitary LH/FSH release and, downstream, gonadal testosterone or estradiol. It is being explored (in small, short-term human research studies) as a way to raise LH pulse frequency and testosterone in men and to probe reproductive disorders. Essentially all human data come from single-dose or short (hours-long) intravenous research infusions in a few dozen supervised volunteers. There is no controlled data on the injectable, repeated, self-administered use seen outside research, and no long-term safety data of any kind. A specific and important pharmacologic caveat is that high bolus doses and continuous exposure cause receptor desensitization/tachyphylaxis, meaning more or continuous drug can produce less response and could theoretically blunt the axis it is meant to stimulate. Purity, dose accuracy, and sterility of non-pharmaceutical peptide material are unverifiable and add infection and contamination risk. This monograph is risk-forward and not an endorsement of use; anyone considering HPG-axis manipulation should do so only under an endocrinologist with bloodwork.

Clinical readoutPeptide · hpg-axis
Hepatic strainNone
CardiovascularNone
HPTA suppressionHigh
Half-life
1 min
Route
Human data are almost e…
Evidence
B
Active
Single intravenous bolu…
1 min2 min3 min4 min6 min
Illustrative single-compartment washout · each mark = one half-life · t½ ≈ Short - on the order of minutes. KP-10 is a small peptide rapidly degraded by peptidases and produces a rapid, transient LH rise, requiring continuous infusion for sustained effect. For the related but longer parent peptide kisspeptin-54, the measured plasma half-life was 27.6 +/- 1.1 min; KP-10 is shorter-acting than KP-54. A precise, independently verified KP-10 human half-life value is not well established in the retrieved primary literature.
Pharmacology

Mechanism of action

Kisspeptin-10 is the shortest kisspeptin fragment retaining full intrinsic activity at the kisspeptin receptor KISS1R (formerly GPR54), a Gq-coupled receptor. It binds KISS1R on hypothalamic GnRH neurons and stimulates pulsatile GnRH secretion; the GnRH then drives anterior-pituitary release of LH (strongly) and FSH (more modestly), which in turn stimulate gonadal sex-steroid output (testosterone in men, estradiol in women). Its action is upstream of GnRH and centrally mediated: peripheral administration stimulates the axis via the hypothalamic GnRH/LHRH system rather than by acting directly on the pituitary. Loss-of-function KISS1R mutations cause normosmic hypogonadotropic hypogonadism and activating mutations cause central precocious puberty, establishing kisspeptin signaling as an obligatory gatekeeper of the reproductive axis. Because KISS1R desensitizes, sustained high-level agonism can paradoxically down-regulate the response.
Kinetics

Pharmacokinetics

Half-life

Short - on the order of minutes. KP-10 is a small peptide rapidly degraded by peptidases and produces a rapid, transient LH rise, requiring continuous infusion for sustained effect. For the related but longer parent peptide kisspeptin-54, the measured plasma half-life was 27.6 +/- 1.1 min; KP-10 is shorter-acting than KP-54. A precise, independently verified KP-10 human half-life value is not well established in the retrieved primary literature.

Active duration

Single intravenous bolus produces a measurable LH rise within ~30 min that is transient; sustained elevation of LH pulsatility and testosterone in humans required continuous IV infusion (studied up to ~11-22.5 h).

Route

Human data are almost exclusively intravenous (bolus and continuous infusion) in supervised research settings. Route/PK are reported here for monitoring and washout context only, not to guide dosing or evade testing.

Metabolism & clearance

Peptide cleared by enzymatic (peptidase) degradation with partial renal handling; for kisspeptin-54 the metabolic clearance rate was 3.2 +/- 0.2 ml/kg/min with volume of distribution 128.9 +/- 12.5 ml/kg. No dedicated KP-10 human clearance/organ-impairment studies were identified.

For monitoring and washout planning, not drug-test evasion.

Reported effects

Physiological & performance effects

  • Dose-dependent acute rise in serum LH after IV bolus in healthy men, with maximal stimulation near 1 microgram/kg and a reduced (blunted) response at 3 microgram/kg, consistent with receptor desensitization at high bolus doses.
  • Continuous IV infusion increases LH pulse frequency, LH secretory burst mass, and serum testosterone in healthy men.
  • Increases LH and testosterone secretion in men with type 2 diabetes and mild biochemical hypogonadism (small proof-of-concept study).
  • Stimulates FSH and testosterone in addition to LH, though the LH effect predominates.
  • Gonadal (Leydig-cell) responsiveness declines with age: in older men the central LH response persisted but the testosterone rise was seen only in younger adult men.
  • Emerging/unproven: kisspeptin signaling has been linked in reviews and largely preclinical or kisspeptin-54 human work to limbic/emotional and sexual-behavior processing; these are not established clinical effects of KP-10.
Safety

Adverse effects by system

Cardiovascular

No adverse cardiovascular effect was reported in the short-term human intravenous studies; however, cardiovascular safety of repeated or long-term KP-10 use has not been studied. No adequate human safety data.

Hepatic

No hepatotoxicity signal was reported in short-term human studies, and as a peptide it is not known to undergo hepatic metabolism that would predict liver injury; however, liver safety has not been formally evaluated. No adequate human data.

Endocrine / HPTA

This is the primary pharmacologic action: KP-10 acutely stimulates the HPG axis (raising LH, FSH, testosterone). The key adverse endocrine concern is receptor desensitization/tachyphylaxis with high bolus or continuous exposure, which blunts the response and could theoretically dysregulate normal pulsatile GnRH/LH signaling. Long-term consequences of exogenous KP-10 on endogenous kisspeptin/GnRH tone are unknown.

Reproductive

Acutely stimulates the reproductive axis (LH/testosterone). Continuous/supraphysiologic exposure can desensitize the axis; effects of repeated exogenous KP-10 on fertility, spermatogenesis, or menstrual function have not been studied. Pregnancy is a particular concern because endogenous kisspeptin rises markedly in pregnancy and exogenous safety is unknown. No adequate human data on chronic use.

Neuropsychiatric

No adverse psychiatric events were reported in the short-term studies. Kisspeptin has been associated with limbic/emotional processing in reviews and preclinical/kisspeptin-54 work, but no established adverse psychiatric effect of KP-10 is documented. No adequate human data.

Renal

Peptide is partly renally handled; no nephrotoxicity was reported in short-term studies and no dedicated renal-safety or renal-impairment data exist. No adequate human data.

Hematologic

No hematologic effects or data identified. No adequate human data.

Dermatologic

No systematic dermatologic data. Injection-site reactions are a general expectation of any injected peptide, and non-sterile/adulterated material adds infection risk, but these were not characterized for KP-10 specifically. No adequate human data.

Recovery

HPTA suppression & recovery

Suppression: Not a classic suppressor - KP-10 activates the HPG axis acutely (raising LH/FSH/testosterone); the relevant risk is desensitization/tachyphylaxis with high or continuous exposure, which can blunt the axis. Any suppression risk from exogenous manipulation of endogenous kisspeptin/GnRH signaling is theoretical and unstudied over the long term.

There is no evidence base for using KP-10 as a post-cycle or HPTA-recovery agent, and its known desensitization behavior argues against assuming it reliably restores the axis. This monograph does not endorse any SERM or multi-drug recovery protocol; if a single SERM is being considered for HPTA recovery that is a separate clinical decision. Anyone with concerns about HPTA function, low testosterone, or fertility should defer to an endocrinologist and obtain baseline and follow-up bloodwork rather than self-treat.

Bloodwork & vitals

Monitoring

Recommended labs & checks
Baseline and follow-up LH and FSHTotal testosterone (men) or estradiol (women)SHBG and, where relevant, free testosteroneProlactin and a full hormonal/reproductive workup if the reason for use is suspected hypogonadism (to identify the actual cause rather than mask it)General safety panel (CBC, comprehensive metabolic/renal and liver panel) as clinically indicated before any repeated dosing

Cadence: Baseline before any use; if used at all, under clinician supervision with re-checks after initiation and periodically thereafter. No validated monitoring schedule exists because chronic use is unstudied.

Warning signs — seek care
  • Signs of hormonal excess (acne, mood change, gynecomastia, testicular changes)
  • Injection-site infection, redness, swelling, or systemic signs of infection (fever, spreading redness)
  • Allergic/hypersensitivity reaction (rash, swelling, difficulty breathing) - seek emergency care
  • Lack of expected response or worsening symptoms, which may reflect desensitization or an untreated underlying disorder - stop and see an endocrinologist
Do not use if

Contraindications

  • Pregnancy and breastfeeding (endogenous kisspeptin is markedly elevated in pregnancy; exogenous safety unknown - avoid)
  • Known or suspected hormone-sensitive conditions or hormone-dependent cancers (theoretical caution given the axis-stimulating, sex-steroid-raising action; discuss with oncologist/endocrinologist)
  • Children/adolescents or anyone with a history of precocious puberty (KISS1R activation drives pubertal onset)
  • Known hypersensitivity to the peptide or excipients
  • Any use without clinician supervision and bloodwork, given absence of long-term safety data and unverifiable purity of non-pharmaceutical material
Combinations

Interaction profile

  • ContraindicatedWith DNP: Additive cardiovascular strain

Check a specific combination in the interaction checker.

Harm reduction

Reducing harm & when to stop

  • The safest position is that KP-10 is an investigational research peptide with no established therapeutic role and no long-term human safety data; do not treat small acute studies as evidence that repeated self-administration is safe.
  • If low testosterone or a reproductive problem is the concern, get a proper diagnosis first - self-administering an axis stimulator can mask an underlying disorder (pituitary, testicular, prolactinoma, systemic illness) that needs specific treatment.
  • More is not better: high bolus doses and continuous exposure cause desensitization/tachyphylaxis, so escalating dose can reduce, not increase, the response and may dysregulate normal signaling.
  • Non-pharmaceutical peptide material has unverifiable identity, purity, dose, and sterility; reconstitution and injection carry infection, contamination, and allergic-reaction risks.
  • Stop and seek medical care for signs of allergic reaction (swelling, difficulty breathing), injection-site or systemic infection (fever, spreading redness), or any acute hormonal symptoms.
  • Avoid entirely in pregnancy/possible pregnancy, in anyone with a hormone-sensitive cancer, and in adolescents.
  • Involve an endocrinologist and use objective bloodwork (LH, FSH, testosterone/estradiol) rather than symptoms alone to make any decisions; this monograph does not provide or endorse a dose, cycle, or stack.
Evidence

Citations (10)

Every clinical claim above is tied to a primary source. Overall evidence grade B — graded to the best available evidence for its core claims.

  1. 01

    KP-10 given as IV bolus in healthy men produces a rapid, dose-dependent rise in LH with maximal stimulation near 1 microgram/kg and a reduced response at 3 microgram/kg; continuous infusion increases LH pulse frequency, pulse mass, and testosterone; tachyphylaxis/desensitization occurs.

    RCTPMID 21632807 ↗

  2. 02

    Kisspeptin-54 IV infusion significantly raises LH, FSH, and testosterone in men; plasma half-life 27.6 min, metabolic clearance 3.2 ml/kg/min, volume of distribution 128.9 ml/kg (used here as PK context for the kisspeptin peptide family).

    RCTPMID 16174713 ↗

  3. 03

    KP-10 increases LH pulse frequency, LH secretion, and testosterone in men with type 2 diabetes and mild biochemical hypogonadism, and was well tolerated in this short proof-of-concept study.

    RCTExploring the pathophysiology of hypogonadism in men with type 2 diabetes: kisspeptin-10 stimulates serum testosterone and LH secretion in men with type 2 diabetes and mild biochemical hypogonadism.PMID 23153270 ↗

  4. 04

    KP-10 (1 microgram/kg IV bolus) raised LH across adult, middle, and advanced age men, but the testosterone rise occurred only in younger adult men, indicating age-related decline in Leydig-cell responsiveness.

    RCTAge-dependent changes in the reproductive axis responsiveness to kisspeptin-10 administration in healthy men.PMID 30590872 ↗

  5. 05

    Peripheral and central kisspeptin-10 stimulate the HPG axis via the hypothalamic GnRH/LHRH system and do not act directly on the pituitary (preclinical mechanistic basis).

    PreclinicalCentral and peripheral administration of kisspeptin-10 stimulates the hypothalamic-pituitary-gonadal axis.PMID 15500545 ↗

  6. 06

    Kisspeptin is the endogenous KISS1R/GPR54 agonist and obligatory regulator of reproduction; loss-of-function mutations cause hypogonadotropic hypogonadism and activating mutations cause precocious puberty; KP-10 is a bioactive cleavage fragment.

    ReviewPMID 18193176 ↗

  7. 07

    Acute IV kisspeptin in healthy human males potently increased LH and significantly increased FSH and testosterone without reported side effects, and kisspeptin is a tool for HPG-axis manipulation in reproductive disorders.

    ReviewThe neuroendocrine physiology of kisspeptin in the human.PMID 17323132 ↗

  8. 08

    Kisspeptin robustly stimulates LH secretion and LH pulse frequency across isoforms/routes/doses in humans; manipulation of kisspeptin signaling is investigational for hypothalamic amenorrhea and hypogonadotropic hypogonadism, with no established chronic therapy.

    ReviewPMID 24615662 ↗

  9. 09

    Kisspeptin signaling has proposed roles in limbic/emotional and sexual-behavior processing (emerging, largely preclinical and kisspeptin-54 human evidence; not established KP-10 clinical effects).

    ReviewPMID 31847025 ↗

  10. 10

    KP-10 (0.3 microgram/kg IV bolus) reliably stimulated LH in healthy men and was used as a physiologic probe with no reported adverse events in short-term studies.

    CohortPMID 28802064 ↗

Last reviewed 2026-07-06 · Verified against PubMed · Educational, not medical advice